Reframe Daily: One Shot Stops 17 Deadly Snake Bites + FDA Approves New Blood Cancer Drug

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible healthtech updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A single antivenom now protects against 17 of Africa's deadliest snakes using antibodies from immunized alpacas; a brand-new vaccine prevents 73% of Salmonella Paratyphi A infections that strike children in developing countries; a two-drug combo significantly extends life for lung cancer patients with EGFR mutations; and the FDA just approved revumenib to treat a hard-to-beat blood cancer with NPM1 mutations.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Personal shares from Christin here →
http://christin.substack.com/

A new nanobody-based antivenom cocktail can protect against 17 different deadly snake species found across Africa. This means future snakebite victims, especially in areas with little access to traditional antivenoms, may soon have a single, effective treatment that works for the most dangerous types of bites. The research shows promising results in animal models, and the antibodies were produced by immunizing alpacas and llamas.

Nanobody-based antivenom for cobra, mamba, and 14 other African snakes shows broad, potent protection

Market readiness: 🙂🙂 (2)
(preclinical and animal studies only; not yet tested in humans, but major step toward broad-spectrum treatment)

A new Salmonella Paratyphi A vaccine, CVD 1902, has proven 73% effective in a phase 2b trial. This vaccine could help prevent enteric fever, an infection that mostly affects children and travelers in regions with limited access to clean water. There are currently no licensed vaccines for Salmonella Paratyphi A, so this marks a critical advance.

Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine: A Randomized Controlled Trial

Market readiness: 🙂🙂🙂 (3)
(completed phase 2b human trial; further studies and regulatory steps needed before real-world use)

A new cancer treatment combo—amivantamab and lazertinib—for patients with EGFR-mutant non-small cell lung cancer (NSCLC) has significantly improved overall survival compared with standard treatment. This gives new hope to people with this challenging type of lung cancer.
Headline:
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Non–Small-Cell Lung Cancer
Market readiness: 🙂🙂🙂🙂 (4)
(already tested in late-stage clinical trials; heading toward or under regulatory review)

FDA approves revumenib for relapsed or refractory AML with NPM1 mutation
Market readiness: 🙂🙂🙂🙂🙂 (5)

Thank you for taking the time to take care of yourself and your loved ones.